BioWisdom Partners with Astrazeneca for Safety Intelligence Program
News Jul 02, 2007
Under the terms of the agreement, AstraZeneca becomes the first partner for BioWisdom’s Safety Intelligence Program (SIP) and joins BioWisdom’s SIP board, an advisory group chaired by industry expert, Dr. Jack Reynolds.
The Safety Intelligence Program applies technology and methodology to deliver an Intelligence System that will be used to support drug safety risk assessment at early stages of the drug discovery process. Financial terms of the agreement were not disclosed.
“We are delighted to have AstraZeneca join our Safety Intelligence Program. We see this long term commitment as a testimony to the benefits that AstraZeneca has already experienced in working with us over the past three years,” said Dr. Julie Barnes, Chief Scientific Officer.
“In AstraZeneca, we see partnership in the Safety Intelligence Program as an important step in enhancing our ability to predict and understand safety related issues early in the Discovery process. Success in the Program is anticipated to result ultimately in the delivery of better innovative medicines to meet patient needs,” said Dr Gerry Oliver, Head of Discovery Support, AstraZeneca.
“I am delighted to see this relationship established and look forward to working with AstraZeneca, BioWisdom and others on the SIP Board. This program provides a critical step towards improving our understanding of many of the major recurring and potentially serious drug-induced adverse events,” said Dr Jack Reynolds.
The ideal drug is one that only affects the exact cells and neurons it is designed to treat, without unwanted side effects. This concept is especially important when treating the delicate and complex human brain. Now, scientists have revealed a mechanism that could lead to this kind of long-sought specificity for treatments of strokes and seizures.READ MORE